

Evaluation of MagicTouch PTA in complex CLTI population

XTOSI

MAGICTOUCH PTA FIRST IN MAN EVALUATION FOR THE TREATMENT OF PAD

Assessment of MagicTouch PTA in CLTI patients by evaluating the primary patency at 6 months in SFA & BTK with follow-up upto 3 years.

50
Patients

COMPLEX CLTI PATIENTS

Diabetes

90%

WIFI Score (4-8)

58%

Dialysis

20%

CAD



36%

PRINCIPAL INVESTIGATOR : PROF. EDWARD CHOKE

Clinical Outcomes*

6 Months

3 Years



Ulcer free status in remaining survivors with intact limbs

100%

Key Takeaways

XTOSI proves sustained long-term safety & efficacy outcomes with >90% Freedom from TLR and >90% Freedom from Major Amputation in SFA. 78% Freedom from TLR and 81% Freedom from Major Amputation in BTK. Promising limb salvage rate was noticed with 100% ulcer free status in intact limbs.

*Presented by Prof. Edward Choke at VIVA 2024. | 1. <https://doi.org/10.1016/j.avsg.2023.12.096>



MagicTouch PTA
SIROLIMUS COATED PTA BALLOON CATHETER

www.conceptmedical.com | info@conceptmedical.com

f t @ in /conceptmedicals

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device. For restricted use only in countries where product registered with applicable health authorities. Approved by USFDA for use in clinical trials only.